Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum-12692

Test info

  
Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
  
12692
  
LAB12692
  
EPS2
  
Dipeptidyl aminopeptidase-like protein 6
EPIES
Metabotropic glutamate receptor 1
Seizures
Spells
Leucine-Rich Glioma Inactivated Protein-1 IgG
  
  • Epilepsy, Interpretation, S
  • AMPA-R Ab CBA, S
  • Amphiphysin Ab, S
  • Anti-Glial Nuclear Ab, Type 1
  • Anti-Neuronal Nuclear Ab, Type 1
  • Anti-Neuronal Nuclear Ab, Type 2
  • Anti-Neuronal Nuclear Ab, Type 3
  • CASPR2-IgG CBA, S
  • CRMP-5-IgG, S
  • DPPX Ab IFA, S
  • GABA-B-R Ab CBA, S
  • GAD65 Ab Assay, S
  • GFAP IFA, S
  • LGI1-IgG CBA, S
  • mGluR1 Ab IFA, S
  • Neurochondrin IFA, S
  • NMDA-R Ab CBA, S
  • Purkinje Cell Cytoplasmic Ab Type 2
  • Purkinje Cell Cytoplasmic Ab Type Tr
For reflex tests, see algorithm on Clinical and Interpretive info tab
  
 
Investigating new onset cryptogenic epilepsy with incomplete seizure control and duration of less than 2 years

Investigating new onset cryptogenic epilepsy plus 1 or more of the following accompaniments:
-Psychiatric accompaniments (psychosis, hallucinations)
-Movement disorder (myoclonus, tremor, dyskinesias)
-Headache
-Cognitive impairment/encephalopathy
-Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, premature graying of hair, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, idiopathic adrenocortical insufficiency), or multiple sclerosis
-History of cancer
       -Smoking history (20+ pack years) or other cancer risk factors
-Investigating seizures occurring within the context of a subacute multifocal neurological disorder without obvious cause, especially in a patient with past or family history of cancer
-A rising autoantibody titer in a previously seropositive patient suggests cancer recurrence

Specimen

  
  • For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication
  • This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, becuase of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received at MCL will be held 1 week and assayed at that time if sufficiently decayed, or canceled if radioactivity remains.
  • Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours
  
Serum
  

Red serum vial/tube, 10 mL

  
4.0 mL
  
2.5 mL
  
  1. Allow sample to clot
  2. Spin
  3. Transfer serum to a Screw cap transfer vial/tube (Mayo T914), labelled as serum, within two (2) hours of sample collection
  

Screw cap transfer vial/tube (Mayo T914)

  

Gold serum separator (SST) tube

  

Immediately following collection, thoroughly mix sample by gently inverting 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection
  3. Transfer serum to a Screw cap transfer vial/tube (Mayo T914), labelled as serum
  

Refrigerated (preferred) - 28 days

Frozen - 28 days

Ambient - 72 hours

Performance

  
Mayo Clinic Laboratories (EPS2): R
  
Daily
  
8 - 12 days
  

Immunofluorescence Assay (IFA), Cell binding assay (CBA), Western blot (WB), Radioimmunoassay (RIA), and Immunoblot (IB)

Clinical and Interpretive info

  

See report

  

Utilization guidelines for neurologic autoimmune panels

Billing

  
86255 x 17
86341

Additional CPT codes (if appropriate):
84182-AGNBS
86256 AGNTS
86256-AMPIS
84182-AMIBS
84182-AN1BS
86256 AN1TS
84182-AN2BS
86256 AN2TS
86256 AN3TS
86256 APHTS
86256 CRMTS
84182-CRMWS
86255-DPPCS
86256-DPPTS
86256-GABIS
86255-GFACS
86256-GFATS
86255-GL1CS
86256-GL1TS
86255 NCDCS
86256 NCDTS
86256-NMDIS
86256 PC2TS
84182-PCTBS
86256-PCTTS

Tracking

  
11/18/2014
  
02/20/2023
  
02/20/2023